HMG

Batch documentation

Overview

Human Menopausal Gonadotropin, generic name Menotropins and abbreviated as HMG, is a mixed-gonadotropin biological purified from postmenopausal-female urine. The source biology works because postmenopausal physiology excretes elevated pituitary gonadotropins as a consequence of lost ovarian feedback inhibition, making the urinary source viable at commercial scale. Historically the released material carries roughly equal FSH and LH bioactivity per IU, and the resulting drug class is approved across ovulation-induction and assisted-reproductive-technology indications under brand names that include Menopur, Repronex, and a small set of biosimilars. The product's distinctive niche inside the gonadotropin category comes from carrying both FSH and LH activity in a single ampoule, which supports follicular development through the FSH arm and luteal-phase progesterone production through the LH arm in a single dispense; recombinant FSH-only alternatives like Gonal-F and Follistim require an LH-source administered separately. For compounding pharmacy and distributor buyers, Vialdyne distributes HMG only to qualified accounts holding the right import-and-dispense licensing for assisted-reproductive or compounding use in the receiving jurisdiction; every order goes through upfront compliance screening before any lot reservation is made. The 75 IU catalogue fill matches the historical Menopur ampoule format around which the clinical-practice ecosystem has built its dosing and inventory infrastructure. As with HCG, biological activity (FSH IU plus LH IU per ampoule, determined by bioassay) matters more than chromatographic purity alone: the urinary source means the released material is a mixed-glycoprotein population, not a single defined molecule, so the RP-HPLC purity and MS identity on the batch COA are necessary but never sufficient, and bioassay potency is available on request and listed on the COA when tested.

Applications & buyer fit

Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.

Primary buyer fit: 503A / 503B compounding pharmacies and regional distributors and re-sellers.

Specifications

CAS

61489-71-2

Appearance

White to off-white lyophilized powder

Purity (HPLC)

Purity & IU potency per COA

Strength

75 iu

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 6 days

MOQ

On request

Lead time

21–45 days

Storage

2–8°C, protect from light

Certificate of Analysis

Representative COA previews for HMG; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

HMG

VD260428-MG110 · 99.43%

Regulatory note

This urine-derived gonadotropin biological carries a high regulatory burden. Purchase is restricted to qualified buyers who hold appropriate licensing in their jurisdiction, with a compliance review required for each order.

Selected literature

1. Devroey P, Pellicer A, Nyboe Andersen A, Arce JC; Menopur in GnRH Antagonist Cycles with Single Embryo Transfer Trial Group. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril. 2012;97(3):561-571.
2. Witz CA, Daftary GS, Doody KJ, Park JK, Seifu Y, Yankov VI, Heiser PW; Menopur in GnRH Antagonist Cycles with Single Embryo Transfer-High Responder (MEGASET-HR) Trial Group. Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection. Fertil Steril. 2020;114(2):321-330.
3. van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, Al-Inany HG. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011;(2):CD005354.
4. Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, Serour GI. Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod Biomed Online. 2008;16(1):81-88.
5. European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone. Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertil Steril. 2002;78(3):520-528.
6. Bordewijk EM, Mol F, van der Veen F, van Wely M. Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis. Hum Reprod Open. 2019;2019(3):hoz008.

Frequently asked questions